share_log

Edwards Lifesciences' (NYSE:EW) Earnings Offer More Than Meets The Eye

Edwards Lifesciences' (NYSE:EW) Earnings Offer More Than Meets The Eye

愛德華生命科學(紐交所:EW)的收益背後隱藏着更多信息
Simply Wall St ·  11/13 18:46

Edwards Lifesciences Corporation's (NYSE:EW) recent earnings report didn't offer any surprises, with the shares unchanged over the last week. Our analysis suggests that shareholders might be missing some positive underlying factors in the earnings report.

愛德華生命科學公司(紐交所:EW)最近的收益報告並沒有帶來任何驚喜,股票在過去一個星期持平。我們的分析表明,股東可能忽略了收益報告中一些積極的潛在因素。

big
NYSE:EW Earnings and Revenue History November 13th 2024
紐交所:EW股票的收益和營業收入歷史數據爲2024年11月13日

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

Importantly, our data indicates that Edwards Lifesciences' profit was reduced by US$266m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect Edwards Lifesciences to produce a higher profit next year, all else being equal.

值得注意的是,我們的數據顯示,由於飛凡項目,愛德華生命科學的利潤在過去一年減少了26600萬美元。雖然由於飛凡項目而扣除款項在首次出現時令人失望,但其中也有一線希望。我們查看了成千上萬家上市公司,發現飛凡項目很常見且通常是一次性的。考慮到這些款項被視爲飛凡,這也並不讓人驚訝。假設這些飛凡支出不會再次發生,我們因此預期愛德華生命科學在明年將實現更高的利潤,其他條件保持不變。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓您想知道分析師對未來盈利能力的預測。幸運的是,您可以單擊此處查看基於其估計的未來盈利能力的互動圖表。

Our Take On Edwards Lifesciences' Profit Performance

我們對愛德華生命科學的利潤表現看法

Because unusual items detracted from Edwards Lifesciences' earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Edwards Lifesciences' earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at 9.9% per year over the last three years. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. Ultimately, this article has formed an opinion based on historical data. However, it can also be great to think about what analysts are forecasting for the future. At Simply Wall St, we have analyst estimates which you can view by clicking here.

由於飛凡項目在過去一年中影響了愛德華生命科學的收益,因此可以說我們可以期待當前季度有改善的結果。由於這個原因,我們認爲愛德華生命科學的盈利潛力至少和表面看起來一樣好,甚至可能更好!而且,其每股收益在過去三年增長了9.9%。歸根結底,要全面考慮,不僅僅是上述因素,如果想要正確了解這家公司。最終,這篇文章是基於歷史數據形成的觀點。不過,想想分析師對未來的預測也會很有幫助。在Simply Wall St,我們有分析師的預估,您可以點擊這裏查看。

This note has only looked at a single factor that sheds light on the nature of Edwards Lifesciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這則說明只關注了一個揭示愛德華生命科學利潤性質的因素。但如果您有能力將注意力集中在細枝末節上,就會有更多發現。例如,許多人認爲高淨資產回報率是有利的商業經濟指標,而另一些人喜歡『跟隨資金』,尋找內部人員正在買入的股票。雖然這可能需要您做一些研究,但您可能發現這個免費的公司集合擁有高淨資產回報率,或者這份持有大量內部持股的股票清單會很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論